Left to right: Christopher Paul James Wightman; James Walsh, PhD; Gregory Todd Bosch; Keith Alan Goldan, CPA; Alan Suggett, BSc, PhD, C Chem, FRSC; Timothy Bruce Anderson; Bishop Julius Allen; Michael Dimitrios Sapountzoglou; Joseph William Birkett.
Christopher Paul James Wightman, Non-Executive Chairman
Mr. Wightman joined PuriCore in 1998 as a Non-Executive Director and was appointed Non-Executive Chairman of the Board of Directors in August 2002. Mr. Wightman is chairman or director of a number of other private UK companies. He previously spent 14 years in the investment banking industry with Goldman Sachs, Bankers Trust, NatWest, and NationsBank. He read law at Nottingham University before joining Arthur Andersen & Co., where he qualified with the Institute of Chartered Accountants. Mr. Wightman is a member of the Nominations Committee.
Gregory Todd Bosch, Chief Executive Officer
Mr. Bosch joined PuriCore in November 2004 as Chief Executive Officer. Prior to joining PuriCore, Mr. Bosch held a variety of management and leadership positions with Baxter International during his 19-year tenure. Most recently, he was Vice President and General Manager of Baxter's BioSurgery division, which experienced growth from $40 million in 1998 to more than $220 million in 2004 under his leadership. Mr. Bosch had international assignments in Austria and Switzerland and he was a board member of Baxter AG, a company with more than 2,500 employees. Mr. Bosch received his BA from Duke University and his MBA from DePaul University. Mr. Bosch is a member of the PuriCore Nominations Committee.
Keith Alan Goldan, CPA, Chief Financial Officer
Mr. Goldan joined PuriCore in October 2004 as the Chief Financial Officer, bringing more than 13 years of experience in business planning and financial management in the life science industry. Previously, Mr. Goldan was Vice President and CFO of Biosyn, Inc., a privately held biotechnology company that was successfully acquired by a publicly traded pharmaceutical company in 2004. He also has worked with ViroPharma Incorporated; Century Capital Associates, a consulting firm specializing in capital strategy for healthcare clients; and with the Healthcare & Life Sciences Practice of KPMG LLP. Mr. Goldan received a BA in Business Management (Finance), cum laude, from the Robert H. Smith School of Business at the University of Maryland and holds an MBA from the Wharton School of Business.
Bishop Julius Allen, Non-Executive Director
Mr. Allen joined PuriCore in March 2003 as a Non-Executive Director and was appointed acting Chief Operating Officer in October 2003 until November 2004. Mr. Allen is currently the Vice President of Customer Supply Chain for Sorrento Lactalis USA, the US division of Lactalis Group, a multinational dairy and cheese group. He was President and COO of Triad Foods Group, Inc., the leading private label delicatessen meat company in the US. He previously held senior management positions at Schlotzsky's Deli, a publicly-listed international franchise restaurant chain; Safeway Inc; HEB Supermarkets; Tom Thumb Supermarkets and other food retail groups. Mr. Allen has a BBA with a concentration in Economics and Finance from the University of Texas. Mr. Allen is a member of the PuriCore Remuneration Committee.
Timothy Bruce Anderson, Independent Non-Executive Director
Mr. Anderson joined PuriCore in September 2006 as an Independent Non-Executive Director. He held various executive management positions from 1972 to 2002 at Baxter International (NYSE: BAX), a leading US medical technology company, including Senior Vice President of Strategy and Business Development; President, Biotech Group; Group Vice President and Chairman, Baxter Europe. Mr. Anderson is also currently a Director of Cerus Corporation (NASDAQ: CERS) and Lake Forest Hospital. Mr. Anderson is a member of the PuriCore Audit Committee.
Joseph William Birkett, Independent Non-Executive Director
Mr. Birkett joined PuriCore in 1999 as an Independent Non-Executive Director. Mr. Birkett is an independent consultant and investor. His career was in finance and global investment banking before forming and running two independent venture capital firms in the 1980s and 1990s. He is currently Chairman of Chelford Group plc, an AIM-listed supply chain software company. Following a BSc in Economics from Sheffield University, he qualified as an FCA with Touche Ross (now Deloitte & Touche LLP). Mr. Birkett is a member of the PuriCore Audit and Nominations Committees.
Michael Dimitrios Sapountzoglou, Non-Executive Director
Mr. Sapountzoglou joined PuriCore in 1999 as a Non-Executive Director. Mr Sapountzoglou brings more than 19 years of investment and finance experience and is currently the Finance Director for Metrostar Management Corp., the shipping arm of the Angelopoulos group, and serves as the corporate finance and investment adviser for the group's other global investment activities. Prior to this, he was a co-founder of Gamma Research, a financial advisory firm focusing on European and Eastern European markets. He was also the Investment Manager for Star Maritime S.A., a private company based in Monte Carlo and part of the Livanos Shipping Group, where he managed and oversaw the Group's proprietary investment portfolios. Mr. Sapountzoglou is a member of the PuriCore Remuneration and Nominations Committees.
Alan Suggett, BSc, PhD, C Chem, FRSC, Independent Non-Executive Director
Dr. Suggett joined PuriCore in September 2006 as an Independent Non-Executive Director. He has more than 20 years of experience in technical and business roles in the medical devices field. He brings strong experience in strategic and governance leadership, most recently related to orthopedics, minimally-invasive surgery, and wound management. He was Group Director of Technology at Smith & Nephew plc. Previously he held senior positions with Smith & Nephew, Scottish & Newcastle Breweries, and Unilever Research. Dr. Suggett is also a Non-Executive Director of Intercytex Group plc (AIM: ICX), Chairman of the Scientific Advisory Board of Photopharmica Limited, Chairman of the Healthcare Technologies Knowledge Transfer Network, a Fellow of the Royal Society of Chemistry, an Honorary Fellow of the Royal College of Physicians, and a Visiting Professor at the University of York.
James Walsh, PhD, Independent Non-Executive Director
Dr. Walsh joined PuriCore in September 2006 as an Independent Non-Executive Director. He has 20 years of general management experience in the healthcare industry with particular experience in diagnostics. He is an Executive Director and Chief Operating Officer with Trinity Biotech Plc (NASDAQ: TRIB). He is also CEO of Stokes Bio Ltd., an Irish-based microfluidics company working in the area of molecular diagnostics. Dr Walsh also holds Non-Executive Director positions with a number of early-stage companies in the life science areas. Previously Dr. Walsh was Managing Director of Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc (AMEX: IMA). Dr Walsh is a graduate of the National University of Ireland and holds a Doctorate in Inorganic Chemistry and Post Doctorate qualifications in Immunochemistry. Dr. Walsh is a member of the PuriCore Remuneration Committee.
